Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
23 Jun 2023
Historique:
medline: 26 6 2023
pubmed: 23 6 2023
entrez: 23 6 2023
Statut: epublish

Résumé

Post-COVID conditions are characterised by persistent symptoms that negatively impact quality of life after SARS-CoV-2 diagnosis. While post-COVID risk factors and symptoms have been extensively described in localised regions, especially in the global north, post-COVID conditions remain poorly understood globally. The global, observational cohort study HVTN 405/HPTN 1901 characterises the convalescent course of SARS-CoV-2 infection among adults in North and South America and Africa. We categorised the cohort by infection severity (asymptomatic, symptomatic, no oxygen requirement (NOR), non-invasive oxygen requirement (NIOR), invasive oxygen requirement (IOR)). We applied a regression model to assess correlations of demographics, co-morbidities, disease severity, and concomitant medications with COVID-19 symptom persistence and duration across global regions. We enrolled 759 participants from Botswana, Malawi, South Africa, Zambia, Zimbabwe, Peru, and the USA a median of 51 (interquartile range (IQR) = 35-66) days post-diagnosis, from May 2020 to March 2021. 53.8% were female, 69.8% were 18-55 years old (median (md) = 44 years old, IQR = 33-58). Comorbidities included obesity (42.8%), hypertension (24%), diabetes (14%), human immunodeficiency virus (HIV) infection (11.6%) and lung disease (7.5%). 76.2% were symptomatic (NOR = 47.4%; NIOR = 22.9%; IOR = 5.8%). Median COVID-19 duration among symptomatic participants was 20 days (IQR = 11-35); 43.4% reported symptoms after COVID-19 resolution, 33.6% reported symptoms ≥30 days, 9.9% reported symptoms ≥60 days. Symptom duration correlated with disease severity (P < 0.001, NIOR vs NOR; P = 0.003, IOR vs NOR), lung disease (P = 0.001), race (P < 0.05, non-Hispanic Black vs White), and global region (P < 0.001). Prolonged viral shedding correlated with persistent abdominal pain (odds ratio (OR) = 5.51, P < 0.05) and persistent diarrhoea (OR = 6.64, P < 0.01). Post-COVID duration varied with infection severity, race, lung disease, and region. Better understanding post-COVID conditions, including regionally-diverse symptom profiles, may improve clinical assessment and management globally. Clinicaltrials.gov (#NCT04403880).

Sections du résumé

Background UNASSIGNED
Post-COVID conditions are characterised by persistent symptoms that negatively impact quality of life after SARS-CoV-2 diagnosis. While post-COVID risk factors and symptoms have been extensively described in localised regions, especially in the global north, post-COVID conditions remain poorly understood globally. The global, observational cohort study HVTN 405/HPTN 1901 characterises the convalescent course of SARS-CoV-2 infection among adults in North and South America and Africa.
Methods UNASSIGNED
We categorised the cohort by infection severity (asymptomatic, symptomatic, no oxygen requirement (NOR), non-invasive oxygen requirement (NIOR), invasive oxygen requirement (IOR)). We applied a regression model to assess correlations of demographics, co-morbidities, disease severity, and concomitant medications with COVID-19 symptom persistence and duration across global regions.
Results UNASSIGNED
We enrolled 759 participants from Botswana, Malawi, South Africa, Zambia, Zimbabwe, Peru, and the USA a median of 51 (interquartile range (IQR) = 35-66) days post-diagnosis, from May 2020 to March 2021. 53.8% were female, 69.8% were 18-55 years old (median (md) = 44 years old, IQR = 33-58). Comorbidities included obesity (42.8%), hypertension (24%), diabetes (14%), human immunodeficiency virus (HIV) infection (11.6%) and lung disease (7.5%). 76.2% were symptomatic (NOR = 47.4%; NIOR = 22.9%; IOR = 5.8%). Median COVID-19 duration among symptomatic participants was 20 days (IQR = 11-35); 43.4% reported symptoms after COVID-19 resolution, 33.6% reported symptoms ≥30 days, 9.9% reported symptoms ≥60 days. Symptom duration correlated with disease severity (P < 0.001, NIOR vs NOR; P = 0.003, IOR vs NOR), lung disease (P = 0.001), race (P < 0.05, non-Hispanic Black vs White), and global region (P < 0.001). Prolonged viral shedding correlated with persistent abdominal pain (odds ratio (OR) = 5.51, P < 0.05) and persistent diarrhoea (OR = 6.64, P < 0.01).
Conclusions UNASSIGNED
Post-COVID duration varied with infection severity, race, lung disease, and region. Better understanding post-COVID conditions, including regionally-diverse symptom profiles, may improve clinical assessment and management globally.
Registration UNASSIGNED
Clinicaltrials.gov (#NCT04403880).

Identifiants

pubmed: 37352144
doi: 10.7189/jogh.13.06020
pmc: PMC10289480
doi:

Banques de données

ClinicalTrials.gov
['NCT04403880']

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

06020

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI069423
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069470
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069470
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068614
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068635
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States

Informations de copyright

Copyright © 2023 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and declare the following activities and relationships: PG reports funding from HVTN, consulting fees from Johnson & Johnson and DSMB activities. The other authors declare no conflicts of interest: KG, CK, JH, LP, MT, PH, RD, JGC, JM, LC, MJ, SL, VK, JH, MDM, SK, DT, NE, AT, RM.

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
PLoS One. 2021 May 3;16(5):e0250602
pubmed: 33939733
Lancet Glob Health. 2022 Sep;10(9):e1247-e1256
pubmed: 35961348
Depress Anxiety. 2019 Jan;36(1):8-17
pubmed: 30188598
Int J Infect Dis. 2022 Sep;122:1044-1051
pubmed: 35908724
Sci Rep. 2022 Apr 20;12(1):6496
pubmed: 35444221
BMC Infect Dis. 2022 Feb 8;22(1):133
pubmed: 35135496
AIDS Care. 2018 Jun;30(6):774-783
pubmed: 29353489
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Int J Clin Pract. 2021 Oct;75(10):e14357
pubmed: 33977626
Pan Afr Med J. 2021 Jan 20;38:65
pubmed: 33889231
Crit Care. 2017 Dec 5;21(1):296
pubmed: 29208005
Stroke. 2021 May;52(5):e117-e130
pubmed: 33878892
BMC Geriatr. 2021 May 19;21(1):321
pubmed: 34011269
Stat Med. 2002 Aug 30;21(16):2409-19
pubmed: 12210625
BMC Infect Dis. 2021 Mar 25;21(1):304
pubmed: 33765941
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Lancet Glob Health. 2020 Aug;8(8):e1018-e1026
pubmed: 32622400
World J Gastroenterol. 2020 May 21;26(19):2323-2332
pubmed: 32476796
Int J Environ Res Public Health. 2022 May 13;19(10):
pubmed: 35627472
Rev Neurosci. 2021 Jan 13;32(3):351-361
pubmed: 33618441
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Int J Environ Res Public Health. 2022 Jan 04;19(1):
pubmed: 35010786
Clin Microbiol Infect. 2022 May;28(5):657-666
pubmed: 35124265
Clin Infect Dis. 2023 Feb 8;76(3):e487-e490
pubmed: 36052466
Front Public Health. 2022 Mar 31;10:856137
pubmed: 35433600
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
Lancet. 2022 Jun 18;399(10343):2263-2264
pubmed: 35717982
J Infect Dis. 2022 Nov 1;226(9):1593-1607
pubmed: 35429399
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Sci Rep. 2021 May 7;11(1):9784
pubmed: 33963250
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Biostatistics. 2014 Apr;15(2):222-33
pubmed: 24292992
Dermatol Ther. 2021 Mar;34(2):e14788
pubmed: 33481314
Int J Infect Dis. 2021 Jan;102:577-583
pubmed: 33176202
Front Med (Lausanne). 2021 Jul 15;8:667623
pubmed: 34336881
Infection. 2022 Oct;50(5):1067-1109
pubmed: 35750943
J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105379
pubmed: 33254369
Mayo Clin Proc. 2020 Aug;95(8):1632-1648
pubmed: 32753138
Am J Infect Control. 2021 Feb;49(2):238-246
pubmed: 32659414
J Med Virol. 2020 Oct;92(10):1902-1914
pubmed: 32293716
Curr Opin Pharmacol. 2022 Apr;63:102203
pubmed: 35255454
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540
Emerg Infect Dis. 2022 Mar;28(3):730-733
pubmed: 35133956
Lancet. 2020 Dec 12;396(10266):1861
pubmed: 33308453

Auteurs

Shelly Karuna (S)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Jorge A Gallardo-Cartagena (JA)

Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru.

Deborah Theodore (D)

Columbia University Physicians & Surgeons, New York, New York, USA.

Portia Hunidzarira (P)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Juan Montenegro-Idrogo (J)

Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru.

Jiani Hu (J)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Megan Jones (M)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Vicky Kim (V)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Robert De La Grecca (R)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Meg Trahey (M)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Carissa Karg (C)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Azwi Takalani (A)

Hutchinson Centre for Research in South Africa, Johannesburg, Republic of South Africa.

Maurine D Miner (MD)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Rebone Maboa (R)

Ndlovu Research Centre, Elandsdoorn, Limpopo, Republic of South Africa.

Lawrence Corey (L)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Katherine Gill (K)

Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, Republic of South Africa.

Shuying Sue Li (SS)

Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH